ARA-290 peptide vial
🛡️ Immune

ARA-290

ARA-290 (Cibinetide)

Also called ARA-290, cibinetide, cibinitide, helix B surface peptide

EPO's repair signal, without the blood effects

ARA-290 is a fragment of EPO, the hormone athletes dope with, with the blood-building part deliberately left out. What remains is the tissue-protective half. It has been through phase 2 trials in people with small-fibre neuropathy, the nerve damage that causes burning feet. It is investigational.

An 11-amino-acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor, the tissue-protective arm of EPO signalling, without raising red blood cell count. It has been studied mainly in small-fibre neuropathy, in phase 2 trials, and it is not an approved medicine.

Half-life
About 2 to 4 minutes
Route studied
Subcutaneous injection (trials)
Status
Not FDA-approved
Emerging Evidence

Human trials published, with more underway

What ARA-290 has been studied for

The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.

Small-fibre neuropathy
Where the trials are. In phase 2 trials in sarcoidosis-related and diabetes-related small-fibre neuropathy, participants reported less pain and some showed measurable regrowth of small nerve fibres in the skin.
Tissue protection generally
The broader theory behind it: the same receptor is involved in protecting tissue under stress, which is why it has been explored beyond nerves.

Mechanism of Action

How ARA-290 works

ARA-290 engages the tissue-protective branch of EPO signaling:

  • Innate repair receptor activation. It binds the EPO receptor and beta-common receptor (CD131) complex that mediates tissue protection, distinct from the classic EPO receptor that drives red blood cell production.
  • Inflammation. In laboratory and preclinical work it dampens inflammatory cytokine signalling.
  • Nerve fibres. Its effect on small nerve fibres is the basis for its study in small-fibre neuropathy.
  • No red blood cell effect. Because it avoids the classic EPO receptor, it does not raise haematocrit.

ARA-290 side effects: what studies reported

Well tolerated in the phase 2 trials. Unlike EPO it does not thicken the blood, which is the reason it was designed this way.

Most commonly reported

  • Injection-site reactions
  • Headache
  • Mild fatigue

Worth knowing

  • It does not raise red blood cell count, which is the point of the modification and the reason it is not an EPO substitute
  • Improvement in nerve trials was gradual over weeks rather than immediate

Source: Phase 2 trials in sarcoidosis-related neuropathy. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about ARA-290 belong with a licensed clinician who knows your history.

Your Genetics & ARA-290

The genes involved in how ARA-290 works

ARA-290 works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.

Chromosome 6TNF-alpha inflammation (−308)

TNF · ••

The -308 G/A promoter variant has been associated with higher TNF-alpha production and studied in inflammatory disease. No study has tested whether it changes response to ARA-290.

Chromosome 7Interleukin-6 inflammation (−174)

IL6 · ••

The -174 G/C variant has been associated with differences in IL-6 levels in some studies. Pathway context only; untested with ARA-290.

Chromosome 6Mitochondrial oxidative defense

SOD2 · ••

The Ala16Val variant has been associated with differences in how the SOD2 antioxidant enzyme reaches mitochondria. Pathway context only.

Chromosome 7Endothelial nitric oxide / microvascular repair

NOS3 · ••

The Glu298Asp variant has been associated with differences in nitric oxide production by blood vessel linings. Pathway context only.

The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.

Which of these variants do you carry?

Your report reads the DNA file you already have against this research.

Read my DNA, $99

Access

Access and legal status

ARA-290 is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.

Your DNA and ARA-290: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →

Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.

Worth knowing about ARA-290

Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.

It is not EPO
The blood-building half was removed on purpose, so it does not act like EPO. It is investigational and not an approved medicine.
Trials were in diagnosed neuropathy
Burning or numb feet have many causes, several of them treatable, and the trials here enrolled people with a confirmed diagnosis.

Last updated

Frequently Asked Questions

How is ARA-290 related to EPO without affecting blood?

EPO signals through two routes: the classic receptor that makes red blood cells, and a separate tissue-protective 'innate repair receptor'. ARA-290 is engineered to activate only the repair route, so it does not raise haematocrit or thicken the blood.

What is ARA-290 mainly studied for?

Its main research focus is small-fibre neuropathy, in phase 2 trials in sarcoidosis and diabetes, along with inflammatory conditions in preclinical work.

Do genes affect ARA-290 response?

No study has tested whether any genotype changes response to ARA-290. TNF, IL6, SOD2 and NOS3 variants have been associated with inflammatory or vascular traits in human studies. A DNA report can show which versions you carry and what that research does and does not show.

Your DNA and ARA-290

What the research says about your variants.

The report

Which ARA-290 variants do you carry?

Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.

Read my DNA, $99
Upload your DNA